Please ensure Javascript is enabled for purposes of website accessibility



We have the knowledge and expertise to handle the most demanding and complex transactions and provide expert, efficient and cost effective services to all our clients. Our commercial understanding and experience of working with leading financial institutions, professional advisers and regulatory bodies enable us to add real value to our clients’ businesses.

View all services


Our experts provide independent guidance spanning advice and training to implementation and evaluation across sustainable investing, regulatory compliance and tech. Our tailored advice meets clients' specific needs, delivering flexible solutions and support.

View all Consulting


Our sector approach relies on smart collaboration between our business divisions, our service lines and our jurisdictions. These sector-based teams have a deep understanding of related businesses and industry dynamics. The specific combination of our highly informed experts helps our clients see around corners.

View all sectors


Ogier provides practical advice on BVI, Cayman Islands, Guernsey, Irish, Jersey and Luxembourg law through our global network of offices across the Asian, Caribbean and European timezones. Ogier is the only firm to advise on this unique combination of laws.

News and insights

Keep up to date with industry insights, analysis and reviews. Find out about the work of our expert teams and subscribe to receive our newsletters straight to your inbox.

Fresh thinking, sharper opinion.

About us

We get straight to the point, managing complexity to get to the essentials. Our global network of offices covers every time zone. 

No Content Set

Ogier advises on $253,000,000 ARYA Sciences Acquisition Corp business combination with Immatics Bio


21 July 2020

Cayman Islands

Ogier's Cayman Islands team has advised ARYA Sciences Acquisition Corp (ARYA), a special purpose acquisition company sponsored by Perceptive Advisors, LLC, on its business combination with Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies.

The business combination was effected by way of merger and share exchange. None of the ARYA's shareholders redeemed their shares in connection with ARYA's shareholder approval. Proceeds from the transaction were approximately $253 million, which included funds held in ARYA's trust account and certain private investment.

As a result of the business combination, the combined company is now known as Immatics N.V. and its shares currently trade on the Nasdaq Capital Market.

Ogier's team was led by partner Angus Davison.

Angus said: "We are delighted to have worked with ARYA and to have been able to offer our expertise on such a significant transaction."

No Content Set